Core Insights - Novo Nordisk has announced the advancement of subcutaneous and oral amycretin into phase 3 development for weight management following positive feedback from regulatory authorities [1][2] - The phase 3 development program is set to begin in the first quarter of 2026, targeting adults with overweight or obesity [2] Product Information - Amycretin is a long-acting GLP-1 and amylin receptor agonist designed for both subcutaneous and oral administration, aimed at treating adults with overweight or obesity and type 2 diabetes [3] - The oral amycretin phase 1 trial evaluated single and multiple ascending doses, with a maximum dose of 100 mg over a treatment duration of up to 12 weeks [4] - The subcutaneous amycretin phase 1b/2a trial focused on safety, tolerability, and pharmacokinetics, with a total treatment duration of up to 36 weeks [5] Company Overview - Novo Nordisk is a leading global healthcare company founded in 1923, headquartered in Denmark, and employs approximately 77,400 people across 80 countries [6] - The company markets its products in around 170 countries and is listed on Nasdaq Copenhagen and the New York Stock Exchange [6]